Thermo Fisher

This asset outlines the comprehensive support and guidance offered by the FAS team for optimizing monoclonal antibody (mAb) manufacturing processes using the Efficient-Pro medium and feeds. Readers will learn about the tailored assistance provided at every stage, including troubleshooting, recommendations

Learn about how Efficient-Pro Medium and Feeds elevate productivity in CHO-K1, CHO-S, and DG44 cells for bioproduction in this comprehensive content piece.

The Gibco Efficient-Pro Medium and Feeds Evaluation Guide provides insights into enhancing monoclonal antibody manufacturing workflows. Offering improved titers, viability, and protein quality in CHO cell lines, it introduces a comprehensive evaluation process for maximizing productivity. Explore this asset for detailed step-by-step guidance and troubleshooting tips

Discover how the Gibco™ Efficient-Pro™ system boosts productivity, enhances cell viability, and ensures superior product quality with minimal impurities. Packed with detailed fed-batch study results, this guide offers actionable insights and practical tips to optimize your bioproduction processes, ensuring you achieve higher yields and consistent, high-quality outcomes. Dive into this indispensable asset to elevate your manufacturing workflow to the next level.

In this asset, you will discover how the Gibco Efficient-Pro system can revolutionize your mAb manufacturing workflow. It provides insights into optimizing CHO cell productivity, enhancing product titers and protein quality, streamlining process efficiency, and leveraging a reliable supply network.

Consistent quantification using qPCR and dPCR technology is essential for obtaining accurate and precise viral vector titers.

The successful transition of drug products between developers and manufacturers is equal parts science and art, defined by enabling processes, a culture of collaboration to support them, and, perhaps most important, a foundation of trust.

Risky Assumptions for Addressing Limited Bioavailability

Whether it’s for scaling-up, moving to another facility, or moving to another outsourcing partner, technology transfers are part of the normal course of business. Learn about the 9 dos and don’ts of executing a successful technology transfer.

Small molecule drug development has changed substantially in recent years. With the heightened focus on molecularly targeted therapies, small molecule active pharmaceutical ingredients (APIs) and drug products are more complex and potent than ever, requiring increasingly specialized manufacturing processes and drug delivery solutions. At the same time, the competitive demand for rapid entry into clinical development—combined with accelerated review pathways—translate into compressed manufacturing and delivery timelines.

Outsourcing projects to CDMOs is becoming increasingly prevalent as drug sponsors look to optimize their supply chain or conserve internal resources for other projects. In 2021 alone, 46% of newly developed drugs were outsourced. Drug sponsors can reap a variety of benefits by outsourcing late-phase projects, but it comes with risks. The technology transfer that must occur to transition a late-phase project to a CDMO is complex and costly. The average cost of a tech transfer is around $1M, so partnering with the wrong CDMO can be a costly mistake.

In the race to market, you need fast, cost-effective, and scientifically proven solutions to seamlessly guide your molecule through early-phase development. Explore these five flexible solutions that enable you to move your molecule through each early development phase with efficiency and speed.

Advancing Drug Development Using in Silico Modeling

When looking to scale-up monoclonal antibody (mAb) manufacturing, a crucial challenge can be delivering sustained or improved product quality with productivity enhancements. Having consistent product quality is essential to ensure patient safety and product efficacy. Manufacturers are therefore placing greater emphasis on optimizing upstream processes. Developed using an advanced multi-omics and bioinformatics modelling approach, the Gibco™ Efficient-Pro™ Medium and Feed System has been specifically formulated to help address productivity and quality challenges. This complete solution brings together two high-performance products, working in total harmony, to accelerate your workflow into a new era. Read the app note and discover the future of mAb manufacturing.

During therapy manufacture, consumable stability is vital to ensure flexible material handling and consistent results. This is particularly true for cell culture media, which is volumetrically the largest bioprocess material component, especially in perfusion workflows. In our new study, we explore the shelf-life of reconstituted Gibco™ High-Intensity Perfusion CHO Advanced Granulation Technology (AGT™) media (HIP CHO AGT media). Chemically defined and animal origin-free, this easy-to-use perfusion medium can provide flexibility with excellent post-reconstitution stability and help you achieve high titers in your CHO cell lines. Discover how HIP CHO AGT media can support the optimization of your monoclonal antibody (mAb) manufacturing.

Nitrite determination in the USP monograph was evaluated with a Dionex IonPac AS15 column using an ICS-5000 HPIC IC system according to the Dalteparin Sodium monograph.

Learn how to develop a robust validation package that supports cell and gene therapy products and their unique features – access our whitepaper.

This whitepaper highlights six key points that pharmaceutical companies should consider when selecting the ideal partner to synthesize an API for them.

Are you looking to ensure compliance to the latest demanding regulations? Do need to be able to easily demonstrate control of your data? With Thermo Scientific™ Chromeleon™ CDS software you can rest assured. Delivering a comprehensive set of compliance tools,